Search results for "glycated hemoglobin"

showing 10 items of 163 documents

Effect on gut microbiota of a 1-y lifestyle intervention with Mediterranean diet compared with energy-reduced Mediterranean diet and physical activit…

2021

ABSTRACT Background The Mediterranean diet is a well-recognized healthy diet that has shown to induce positive changes in gut microbiota. Lifestyle changes such as diet along with physical activity could aid in weight loss and improve cardiovascular risk factors. Objectives To investigate the effect of an intensive lifestyle weight loss intervention on gut microbiota. Methods This is a substudy of the PREDIMED-Plus (Prevención con Dieta Mediterránea-Plus), a randomized controlled trial conducted in overweight/obese men and women (aged 55–75 y) with metabolic syndrome. The intervention group (IG) underwent an intensive weight loss lifestyle intervention based on an energy-restricted Mediterr…

Male0301 basic medicineWeight lossMediterranean dietNutritional Status Dietary Intake and Body CompositionMedicine (miscellaneous)PhysiologyOverweightGut floraDiet MediterraneanAcademicSubjects/MED00160Feceschemistry.chemical_compound0302 clinical medicineWeight lossRNA Ribosomal 16SMedicinePhylogenyMetabolic SyndromeNutrition and DieteticsbiologyMiddle AgedOriginal Research CommunicationsRNA BacterialFemalemedicine.symptomEnergy restriction030209 endocrinology & metabolismGut microbiotaAcademicSubjects/MED0006003 medical and health sciencesMediterranean dietHumansObesityExerciseLife StyleAgedCaloric RestrictionBacteriabusiness.industryLachnospiraceaemedicine.diseasebiology.organism_classificationObesityGastrointestinal Microbiome030104 developmental biologychemistryGlycated hemoglobinMetabolic syndromeEnergy IntakebusinessThe American Journal of Clinical Nutrition
researchProduct

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

2017

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothel…

Male0301 basic medicineendocrine system diseasesDiabetic CardiomyopathiesFPS-ZM1 RAGE inhibitorClinical BiochemistryAorta ThoracicRAGE receptor for AGEICAM-1 intercellular adhesion molecule-1ECL enhanced chemiluminescence030204 cardiovascular system & hematologyDPP-4 dipeptidyl peptidase-4medicine.disease_causeTNF-α tumor necrosis factor-αBiochemistryeNOS endothelial •NO synthase (type 3)0302 clinical medicineGlucosidesecSOD extracellular superoxide dismutaseInsulin-Secreting CellsCCL-2 see MCP-1HyperlipidemiaHyperinsulinemiaGTN glyceryl trinitrate (nitroglycerin)IFN-γ interferon-γDHE dihydroethidineEndothelial dysfunctionEndothelial dysfunctionIL-6 interleukin-6lcsh:QH301-705.5HO-1 heme oxygenase-1lcsh:R5-920ICAM-1NG normoglycemiaDiabetesNox catalytic subunit of NADPH oxidaseSGLT2 inhibitorβ-cell contentL-012 8-amino-5-chloro-7-phenylpyrido[34-d]pyridazine-14-(2H3H)dione sodium saltChIP chromatin immunoprecipitationC-Reactive ProteinCRP C-reactive proteinAGE advanced glycation end productsHbA1c glycohemoglobinlcsh:Medicine (General)Research PaperZucker diabetic fatty ratsmedicine.medical_specialtyDMSO dimethylsulfoxideMCP-1 monocyte-chemoattractant-protein-1qRT-PCR quantitative reverse transcription polymerase chain reactionZDF Zucker diabetic fatty (rat)Low-grade inflammation03 medical and health sciencesROS reactive oxygen speciesSodium-Glucose Transporter 2Physiology (medical)Internal medicineDiabetes mellitusPKC protein kinase CEmpagliflozinmedicineAnimalsHypoglycemic AgentsBenzhydryl CompoundsCOX2 cyclooxygenase-2SGLT2i SGLT2 inhibitorSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinACh acetylcholinebusiness.industryOrganic Chemistrynutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseH2K9me2 histone3 lysine9 dimethylationRatsRats ZuckerDHFR dihydrofolate reductaseSGLT2 sodium-glucose co-transporter-2Oxidative StresssGC soluable guanylyl cyclaseGlucose030104 developmental biologyEndocrinologylcsh:Biology (General)ALDH-2 mitochondrial aldehyde dehydrogenaseEndothelium VascularAGE/RAGE signalingHG hyperglycemiabusinessOxidative stressRedox Biology
researchProduct

Influence of habitual dairy food intake on LDL cholesterol in a population-based cohort

2021

Background: Cholesterol has a pivotal role in human physiology, exerting both structural and functional activity. However, higher blood cholesterol levels, especially low-density lipoprotein cholesterol (LDL-C), are a major cardiovascular risk factor. Therefore, special attention has been given to the effect of dietary factors in influencing LDL-C blood levels. In particular, much research has focused on dairy products, since they are a main component of different dietary patterns worldwide. A large body of evidence did not support the hypothesis that dairy products significantly increase circulating LDL-C, but no definitive data are available. Hence, we aimed to assess the relationships am…

MaleAdultPopulationlcsh:TX341-641Blood PressureLongitudinal StudieBody fat percentageArticleBody Mass IndexLDLCohort StudiesDairychemistry.chemical_compoundAnimal scienceCheeseSurveys and QuestionnairesMedicineAnimalsHumansLongitudinal StudiesSettore MED/49 - Scienze Tecniche Dietetiche ApplicateeducationSicilyeducation.field_of_study...Nutrition and Dieteticsbusiness.industryCholesterolWaist-Hip RatioAnimalFeeding BehaviorCholesterol LDLAnthropometryMiddle AgedRicottaBlood pressureCholesterolMilkchemistryCohortFemalelipids (amino acids peptides and proteins)Glycated hemoglobinDairy ProductsbusinessBody mass indexlcsh:Nutrition. Foods and food supplyFood Science
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct

Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis …

2018

This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabetes with executive function (EF); (b) the effect of BMI on both type 2 diabetes and EF; (c) the association between glycaemia control and EF in type 2 diabetes. 6823 older individuals with overweight/obesity and metabolic syndrome participating in the PREDIMED-PLUS study, were assessed with a battery of cognitive tests and a medical interview. ANOVA showed a significantly worse performance on EF in type 2 diabetes vs. non-diabetic individuals. Two complementary models were displayed: (1) in the whole sample, the presence of type 2 diabetes, depressive symptoms and BMI had a direct negative ef…

MaleCross-sectional studyhumanosType 2 diabetesOverweightPersones gransBody Mass Index0302 clinical medicineOlder people diseasesMedicine030212 general & internal medicineDiabetes Treatment AdherenceCognitive declineMalalties de les persones gransmediana edad2. Zero hungerMetabolic SyndromeancianoMultidisciplinaryDiabetisCognitive ageingQDiabetesRType 2 diabetesMiddle Aged3. Good healthNeurologydiabetes mellitusMedicineObesitatFemalemedicine.symptomPREDIMEDmedicine.medical_specialtyMedicinaScienceArticle03 medical and health sciencesOlder populationDiabetes mellitusInternal medicineApnoeaHumansCognitive DysfunctionObesityobesidadAgedGlycated Hemoglobinbusiness.industryíndice de masa corporalBaseline Cross-sectional AnalysisCognitive neuroscienceCognitive Function PerformanceOverweightmedicine.diseaseObesityCross-Sectional StudiesDiabetes Mellitus Type 2StudyMetabolic syndromeOlder peoplebusinessBody mass index030217 neurology & neurosurgeryestudios transversalesGlycaemic Control
researchProduct

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison

2015

AimsImproving glycaemic control in people with Type1 diabetes is known to reduce complications. Our aim was to compare glycaemic control among people with Type1 diabetes using data gathered in regional or national registries. MethodsData were obtained for children and/or adults with Type1 diabetes from the following countries (or regions): Western Australia, Austria, Denmark, England, Champagne-Ardenne (France), Germany, Epirus, Thessaly and Thessaloniki (Greece), Galway (Ireland), several Italian regions, Latvia, Rotterdam (The Netherlands), Otago (New Zealand), Norway, Northern Ireland, Scotland, Sweden, Volyn (Ukraine), USA and Wales) from population or clinic-based registries. The sampl…

MaleDenmarkEndocrinology Diabetes and Metabolismmetabolic-controlregistryEndocrinologyGermanyInsulinMedicineadolescentsRegistriesYoung adultNetherlandseducation.field_of_studyGreeceNorway18 countriesClinical PracticeEnglandItalyAustriaPractice Guidelines as TopicFemaleFranceGuideline AdherenceUkraineAdultcomplicationsAdolescentPopulationNorthern IrelandNorthern irelandAge and sexYoung AdultInsulin Infusion SystemschildrenDiabetes mellitusInternal MedicineHumansHypoglycemic AgentscareeducationchildhoodGlycated HemoglobinSwedenType 1 diabetesWalesbusiness.industryWestern Australiamedicine.diseaseLatviaiddmUnited StatesDiabetes Mellitus Type 1ScotlandSample size determinationOptometrybusinessIrelandNew ZealandDemographyDiabetic Medicine
researchProduct

Potential influence of Type A personality on plasma C-reactive protein levels in people with diabetes

2016

IF 4.693; Aim. Type A personality, although classically known as a factor linked to increased vascular risk, has recently been associated with increased survival in patients with diabetes. As low-grade inflammation predicts a poor outcome, the present study explored the potential associations between Type A and plasma levels of C-reactive protein (CRP) in diabetes. Methods. Type A personality was assessed by the Bortner questionnaire in people with diabetes. The association between Type A and plasma CRP levels was examined by multivariable linear regression, and structural equation modelling (SEM) was performed to determine the impact of the major clinical, biological and psychological conf…

MaleEndocrinology Diabetes and Metabolism[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionType 2 diabetesBody Mass Index0302 clinical medicineEndocrinologyc-reactive proteinWeight lossself-care030212 general & internal medicineProspective cohort studymedia_common2. Zero hungerbiologydiabetesGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMiddle Aged[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismanxiety3. Good healthFemalemedicine.symptomweight-lossAdultmedicine.medical_specialtymedia_common.quotation_subjectprospective cohort030209 endocrinology & metabolism03 medical and health sciencesInternal medicineDiabetes mellitus[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyInternal MedicinemedicineHumansPersonalityAgedGlycated Hemoglobintype abusiness.industrybehaviorC-reactive proteinassociationType A PersonalityType A and Type B personality theorymedicine.disease5-factor modelmortalityEndocrinologyDiabetes Mellitus Type 2personalityinflammationbiology.proteinbusinesscoronary-heart-disease[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-…

2017

Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…

MaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologialaw.inventionchemistry.chemical_compound0302 clinical medicineEndocrinologydiabetes dapaglifozinGlucosidesRandomized controlled triallawInsulin03.02. Klinikai orvostanDapagliflozinMiddle AgedDiabetes and MetabolismTreatment OutcomeCombinationDrug Therapy CombinationFemaleType 1Adultmedicine.medical_specialtyDiabetic ketoacidosis030209 endocrinology & metabolismPlacebo03 medical and health sciencesDrug TherapyDiabetes managementDiabetes mellitusInternal medicineDiabetes MellitusInternal MedicinemedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment OutcomeAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyGlycated HemoglobinType 1 diabetesbusiness.industryBody Weightmedicine.diseaseHypoglycemiaSurgeryDiabetes Mellitus Type 1chemistrybusinessThe Lancet Diabetes & Endocrinology
researchProduct

Parent-adolescent conflict, treatment adherence and glycemic control in Type 1 diabetes: the importance of adolescent externalising symptoms.

2013

Parent-adolescent conflict has been demonstrated to relate to treatment adherence and glycemic control in adolescents with Type 1 diabetes. The present longitudinal study investigated how these variables were interrelated over time, and examined whether externalising and internalising symptoms function as mediating variables. A total of 109 adolescents with diabetes participated at four annual time points and completed measures on conflict with parents, internalising and externalising symptoms. Information on treatment non-adherence and glycemic control was obtained from treating physicians. Cross-lagged analyses from a structural equation modelling approach indicated that father-adolescent…

MaleLongitudinal studyTime FactorsAdolescentTreatment adherenceControl (management)Models PsychologicalStructural equation modelingDevelopmental psychologyConflict PsychologicalDiabetes mellitusmedicineHumansLongitudinal StudiesParent-Child RelationsChildApplied PsychologyGlycemicGlycated HemoglobinType 1 diabetesPublic Health Environmental and Occupational HealthGeneral MedicineGeneral Chemistrymedicine.diseaseSelf CareDiabetes Mellitus Type 1Adolescent BehaviorPatient ComplianceFemalePsychologyPsychologyhealth
researchProduct

1H NMR-based metabolomics studies of urine reveal differences between type 1 diabetic patients with high and low HbAc1 values

2012

Abstract The aim of this study was to investigate relation between level of HbAc1 and concentration of metabolites in urine of T1D patients. To test this hypothesis the 1 H NMR (proton nuclear magnetic resonance) target analysis of crucial urine metabolites combined with chemometric approach were applied. Urine samples were collected from 30 children and teenagers aged 4–19 with T1D and 12 healthy children, aged 9, as control group. Patients were divided into two groups according to their level of glycated hemoglobin (HbA1c): below (L-T1D) and above 6.5% (H-T1D). The multivariate data analysis (OPLS-DA) was used to explore data and generate the models for selected groups of patients. Two ta…

MaleMagnetic Resonance SpectroscopyAdolescentendocrine system diseasesMetaboliteClinical BiochemistryPharmaceutical ScienceTarget analysisUrineAnalytical ChemistryYoung Adultchemistry.chemical_compoundMetabolomicsValineDrug DiscoveryHumansMetabolomicsAmino AcidsChildSpectroscopyGlycated HemoglobinAlanineChromatographynutritional and metabolic diseasesDiabetes Mellitus Type 1GlucosechemistryBiochemistryChild PreschoolProton NMRFemaleGlycated hemoglobinJournal of Pharmaceutical and Biomedical Analysis
researchProduct